Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F20%3AA21025LM" target="_blank" >RIV/61988987:17110/20:A21025LM - isvavai.cz</a>
Alternative codes found
RIV/00216224:14110/20:00115336 RIV/65269705:_____/20:00072661 RIV/00843989:_____/20:E0108383
Result on the web
<a href="https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13358" target="_blank" >https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ejh.13358</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/ejh.13358" target="_blank" >10.1111/ejh.13358</a>

Result language
angličtina
Original language name
Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients
Original language description
Objectives Progress in multiple myeloma treatment allows patients to achieve deeper responses, for which the assessment of minimal residual disease (MRD) is critical. Typically, bone marrow samples are used for this purpose; however, this approach is site-limited. Liquid biopsy represents a minimally invasive and more comprehensive technique that is not site-limited, but equally challenging. Methods While majority of current data comes from short-term studies, we present a long-term study on blood-based MRD monitoring using tumor-specific cell-free DNA detection by ASO-qPCR. One hundred and twelve patients were enrolled into the study, but long-term sampling and analysis were feasible only in 45 patients. Results We found a significant correlation of quantity of tumor-specific cell-free DNA levels with clinically meaningful events [induction therapy (P = .004); ASCT (P = .012)]. Moreover, length of cfDNA fragments is associated with better treatment response of patients. Conclusions These results support the concept of tumor-specific cell-free DNA as a prognostic marker.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology

Project
<a href="/en/project/NV17-29343A" target="_blank" >NV17-29343A: Bone marrow microenvironment analysis in extramedullary relapse of multiple myeloma</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)